BioVaxys and SpayVac-for-Wildlife Expand License Agreement Into Commercial Aquaculture

posted Apr 24, 2025 9:00am  by  BioVaxys Technology Corp.
BioVaxys President and Chief Operating Officer Kenneth Kovan. "Based on the superior profile of SpayVac vaccines and the U.S. market potential with feral horses and deer, we are anticipating a healthy revenue stream from royalties on sales of SpayVac. With huge global markets for horses and deer, such as Australia, and the expansion into commercial aquaculture including the farm-raised fish market, SpayVac is positioned to become a significant player in the animal health field." ...read more